GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » NonCurrent Deferred Liabilities

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) NonCurrent Deferred Liabilities : $1.02 Mil (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

NewAmsterdam Pharma Co NV's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $1.02 Mil.

NewAmsterdam Pharma Co NV NonCurrent Deferred Liabilities Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV NonCurrent Deferred Liabilities Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
- - 4.79 1.02

NewAmsterdam Pharma Co NV Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial - 7.77 4.79 3.18 1.02

NewAmsterdam Pharma Co NV NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Business Description

Traded in Other Exchanges
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Headlines

From GuruFocus

NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors

By Stock market mentor Stock market mentor 02-06-2023

NewAmsterdam Pharma to Present at Jefferies Healthcare Conference

By sperokesalga sperokesalga 05-31-2023